Recent Posts
- Ukraine recovery should be based on development of territorial communities, innovations, involvement of professional domestic community – results of ESUR forum 29.06.2023
- Ukraine repatriates five more seriously wounded Russian POWs 10.04.2023
- Rada intends to include history of Ukraine, foreign language in final certification for general secondary education 10.04.2023
- Rada terminates protocol on joint anti-terrorist measures in CIS territories for Ukraine 10.04.2023
- 100 Ukrainians, incl defenders of Mariupol, returned according to swap procedure – Yermak 10.04.2023
Insulin manufacturer Indar sees net profit rise by 6.4 times in 2021
KYIV. Jan 11 (Interfax-Ukraine) – Insulin producer PrJSC Indar (Kyiv) increased its net profit by 6.4 times in 2021 from UAH 117,000 in 2020 to UAH 744,000.
According to the data in the information disclosure system of the National Securities and Stock Market Commission, the net income from the sales in 2021 increased by almost 1.3 times compared to 2020, to UAH 753.184 million.
As reported, Indar (Kyiv) in 2020 reduced its net profit by over 370 times from UAH 43.017 million in 2019 to UAH 117,000. Net income from the sales in 2020 decreased by 1.6 times compared to 2019, to UAH 591.543 million.
PrJSC Indar, established by the decision of the Cabinet of Ministers of Ukraine in 1997 on the basis of the Kyiv Meat Processing Plant, is a subsidiary of the state company PJSC Ukrmedprom, which owns 70.7% of the total number of shares. Another 29.3% stake in the company belongs to Luraq investments limited (Cyprus).
The manufacturer is included in the list of state-owned objects of strategic importance for the economy and security of the state, and is a member of the Association of Pharmaceutical Manufacturers of Ukraine.